Skip to content
CompletedPhase 1

Repeat Dosing of Psilocybin in Migraine Headache

NCT04218539 · Yale University

Closed to entry
Status
Not accepting participants
Phase 1
Phase
18
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

In seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses. In seeking to identify an underlying mechanism in psilocybin's effects, neuroinflammatory markers for migraine headache will be measured.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Change in migraine attack frequency

    Measured over From two weeks before the first session to two months after second session using a headache diary

  • Change in pain intensity of migraine attacks

    Measured over From two weeks before the first session to two months after second session using a headache diary

  • Change in duration of migraine attacks

    Measured over From two weeks before the first session to two months after second session using a headache diary

  • Change in intensity of photophobia (light sensitivity)

    Measured over From two weeks before the first session to two months after second session using a headache diary

  • Change in intensity of phonophobia (noise sensitivity)

    Measured over From two weeks before the first session to two months after second session using a headache diary

  • Average intensity of nausea/vomiting

    Measured over From two weeks before the first session to two months after second session using a headache diary

  • Change in functional disability

    Measured over From two weeks before the first session to two months after second session using a headache diary

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

21 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Diagnosis of migraine headache per ICHD-3 criteria * Typical pattern of migraine attacks with approximately two migraines or more weekly * Attacks are managed by means involving no more than twice weekly triptan use Exclusion Criteria: * Axis I psychotic or manic disorder (e.g., schizophrenia, bipolar I, depression with psychosis) * Axis I psychotic or manic disorder in first degree relative * Unstable medical condition; severe renal, cardiac, or hepatic disease; pacemaker; or serious central nervous system pathology * Pregnant, breastfeeding, lack of adequate birth control * History of intolerance to psilocybin, lysergic acid diethylamide (LSD), or related compounds * Drug abuse within the past 3 months (excluding tobacco) * Urine toxicology positive to drugs of abuse * Alcohol use of \>21 drinks per week (males); \>14 drinks per week (females; NIAAA guidelines) * Use of alcohol in the week prior to the first test day * Use of vasoconstrictive medications (i.e., sumatriptan, pseudoephedrine, midodrine) within 5 half-lives of test days * Use of serotonergic antiemetics (i.e., ondansetron) in the past 2 weeks * Use of antidepressant medication (i.e., TCA, MAOI, SSRI) in the past 6 weeks * Use of steroids or certain other immunomodulatory agents (i.e., azathioprine) in the past 2 weeks * Use of migraine onabotulinum toxin (i.e., Botox) or monoclonal antibodies against CGRP or its receptor (i.e., erenumab) in the past month or while therapeutic effects are still present

Where

1 study site

FacilityCityRegionCountry
VA Connecticut Healthcare SystemWest HavenConnecticutUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT04218539 on ClinicalTrials.gov →

Last updated in the registry 2024-02-09. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits